Compare DKI & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DKI | IMRN |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | Hong Kong | Australia |
| Employees | 19 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 9.6M |
| IPO Year | N/A | 2016 |
| Metric | DKI | IMRN |
|---|---|---|
| Price | $4.80 | $1.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 76.1K | ★ 123.8K |
| Earning Date | 05-11-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.68 |
| 52 Week High | $11.80 | $2.38 |
| Indicator | DKI | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 48.72 |
| Support Level | $0.39 | $0.72 |
| Resistance Level | $6.80 | $1.24 |
| Average True Range (ATR) | 0.80 | 0.11 |
| MACD | -0.22 | -0.02 |
| Stochastic Oscillator | 16.15 | 36.45 |
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.